Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Torrent Pharma

    Jump to

    • Torrent to sell Calcigard brand following CCI reservations

      Following the JB acquisition, Torrent commands over 90% market share in nifedipine market prompting CCI to suggest remedial action

    • Zydus, Torrent Pharma join hands to co-market Semaglutide injection

      As part of the agreement, Torrent Pharma will pay an upfront licensing fee to Zydus

    • Hold Torrent Pharma: target of Rs 4150: ICICI Securities

      ICICI Securities recommended hold rating on Torrent Pharma with a target price of Rs 4150 in its research report dated February 16, 2026.

    • Neutral Torrent Pharma; target of Rs 4300: Motilal Oswal

      Motilal Oswal recommended Neutral rating on Torrent Pharma with a target price of Rs 4300 in its research report dated February 14, 2026.

    • Torrent Pharma shares gain on JB Chemicals stake increase, zero USFDA observation

      Torrent Pharma Share Price | The USFDA inspection at Torrent Pharma’s Dahej facility conducted from January 19–23 concluded with zero observations.

    • Torrent Pharma lines up mega $1.4 billion acquisition-funding bond sale: Report

      Torrent also plans to raise Rs 1,500 crore via commercial paper to fund its acquisition of a controlling stake in JB Chemicals & Pharmaceuticals

    • Torrent Pharma Consolidated September 2025 Net Sales at Rs 3,302.00 crore, up 14.3% Y-o-Y

    • Neutral Torrent Pharma; target of Rs 3770: Motilal Oswal

      Motilal Oswal recommended Neutral rating on Torrent Pharma with a target price of Rs 3770 in its research report dated November 08, 2025.

    • Torrent Pharma Standalone September 2025 Net Sales at Rs 2,762.00 crore, up 13.48% Y-o-Y

    • Hold Torrent Pharma: target of Rs 3530 : ICICI Securities

      ICICI Securities recommended hold rating on Torrent Pharma with a target price of Rs 3530 in its research report dated November 09, 2025.

    • Torrent Pharma Q2 net profit jumps 30% to Rs 591 crore

      The company said its India revenue stood at Rs 1,820 crore during the period under review, up 12 per cent, led by outperformance in focus therapies

    • Hold Torrent Pharma: target of Rs 3530: ICICI Securities

      ICICI Securities recommended hold rating on Torrent Pharma with a target price of Rs 3530 in its research report dated July 29, 2025.

    • Torrent Pharma Consolidated June 2025 Net Sales at Rs 3,178.00 crore, up 11.16% Y-o-Y

    • Torrent Pharma Standalone June 2025 Net Sales at Rs 2,616.00 crore, up 7.3% Y-o-Y

    • Torrent Pharma Q1 net profit up 20% at Rs 548 crore

      The company's India revenues rose by 11% YoY to Rs 1,811 crore in the April-June period.

    • Hold Torrent Pharma; target of Rs 3500: ICICI Securities

      ICICI Securities recommended hold rating on Torrent Pharma with a target price of Rs 3500 in its research report dated July 01, 2025.

    • Gainers & Losers: Top 10 stocks that moved the most on June 30

      At close, the Sensex was down 452.44 points or 0.54 percent at 83,606.46, and the Nifty was down 124.00 points or 0.48 percent at 25,513.80. About 2,151 shares advanced, 1,538 shares declined, and 133 shares unchanged.

    • Neutral Torrent Pharma; target of Rs 3430: Motilal Oswal

      Motilal Oswal recommended Neutral rating on Torrent Pharma with a target price of Rs 3430 in its research report dated June 30, 2025.

    • Quick Take: Torrent Pharma puts the money where its heart is

      Torrent’s India business has been outperforming the domestic market

    • Torrent Pharma shares rise 4% after Rs 25,689-crore JB Chemicals deal; HSBC maintains buy

      Torrent Pharma share price: The deal is expected to strengthen Torrent's market share in the Indian pharmaceutical market and diversify its platform into contract development and manufacturing.

    • Torrent Pharma to acquire controlling stake in JB Pharma from KKR at Rs 25,689 crore valuation

      The transaction between Torrent and JB Pharma will unfold in two distinct phases

    • Torrent Pharma revives talks to acquire KKR’s stake in JB Pharma; deal expected soon

      KKR’s stake is worth approximately Rs 13,400 crore considering the J B Pharma stock’s closing price of Rs 1,802.9 per share on June 27.

    • Torrent Pharma Standalone March 2025 Net Sales at Rs 2,433.00 crore, up 13.53% Y-o-Y

    • Neutral Torrent Pharma; target of Rs 3410: Motilal Oswal

      Motilal Oswal recommended Neutral rating on Torrent Pharma with a target price of Rs 3410 in its research report dated January 25, 2025.

    • Torrent Pharma Consolidated December 2024 Net Sales at Rs 2,809.00 crore, up 2.82% Y-o-Y

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347